oncology
Melanoma

Study clarifies optimal duration of anti-PD-1 checkpoint inhibitor therapy

Patients with advance melanoma may be able to discontinue treatment with anti-PD-1 therapy after six months with a low risk of relapse, according to findings from a real-world cohort that included Australian patients. After a median follow up of 18 months after electively discontinuing pembrolizumab or nivolumab, 78% of patients remained free of progression, a ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic